Inspire Medical announced clinical outcomes data for its latest-generation Inspire V neuromodulation system.
The Minneapolis-based company reported outcomes from a clinical study in Singapore and its limited U.S. launch. That data includes single-site experience at two leading centers. The company plans to present data at the American Otolaryngology-Head and Neck Surgery (AAO-HNS) and International Surgical Sleep Society (ISSS) meetings taking place over the next several days.
Related: Pulse Biosciences shares strong first-in-human PFA data
Inspire V, the company’s next-generation sleep apnea therapy system, launched in the U.S. earlier this year. The system includes a next-generation neurostimulator and associated Bluetooth patient remote and physician programmer. The pacemaker-like device delivers mild electrical stimulation to the hypoglossal nerve, which controls tongue muscles, to treat obstructive sleep apnea (OSA).
The system’s key feature comes in the form of internal sensing, eliminating the need for a pressure-sensing lead. This design delivers closed-loop stimulation to optimize therapy outcomes.
“We are incredibly excited to publish first-time clinical evidence on the Inspire V system. The design of the Inspire V system captures experience built over 25 years with Inspire therapy including over 100,000 patients implanted, and we are proud to provide the initial data from this advanced platform,” stated Tim Herbert, chair and CEO of Inspire Medical Systems. “Our initial experience raises the bar for what a successful therapy needs to achieve for both safety and efficacy. The data show that the Inspire V system provides very high and consistent patient adherence of over six hours per night which a patient’s physician can monitor with our SleepSync patient management platform.”
